Clinical relevance of N-acetyltransferase (NAT2) genetic polymorphism;Pertinence clinique du polymorphisme génétique de la N-acétyltransferase de type 2 (NAT2)

Therapie

Volumn 57, Issue 5, 2002, Pages 427-431

  Furet, Y ^a   Bechtel, Y ^b   Le Guellec, C ^a   Bechte, P R ^b   Autret Leca, E ^a   Paintaud, G ^a  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b NONE

Author keywords

Acetylation polymorphism; Adverse drug reactions; Carcinogenesis; Genotype; N acetyltransferase 2; NAT2; Phenotype

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; DAPSONE; ISONIAZID; SALAZOSULFAPYRIDINE; SULFONAMIDE;

ACETYLATOR PHENOTYPE; ARTICLE; BLADDER CANCER; BREAST CANCER; CARCINOGENESIS; COLORECTAL CANCER; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERSENSITIVITY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LIVER CANCER; LUPUS ERYTHEMATOSUS; MESOTHELIOMA; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ACETYLATION; ARYLAMINE N-ACETYLTRANSFERASE; DRUG HYPERSENSITIVITY; GENOTYPE; HUMANS; KINETICS; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 17144435003     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Blum M, Grant DM, McBride W, et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990; 9: 193-203
2. Cribb AE, Isbrucker R, Levatte T, et al. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics 1994; 4: 166-70
3. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5: 1-17
4. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269-96
5. Grant DM, Morike K, Eichelbaum M, et al. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest 1990; 85: 968-72
6. Graf T, Broly F, Hoffmann F, et al. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol 1992; 43: 399-403
7. Cascorbi I, Drakoulis N, Brockmöller J, et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum genet 1995; 57: 581-92
8. Agundez JAG, Olivera M, Martinez C, et al. Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics 1996; 6: 423-8
9. Attitallah S, Bechtel YC, Belkahia Ch, et al. Analysis of N-acetyltransferase (NAT2) in three ethnic groups in Tunisia. Therapie 2000; 55: 361-9
10. Kaufmann GR, Wenk M, Taeschner W, et al. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1996; 60: 62-7
11. O'Neil WM, Gilfix BM, DiGirolamo A, et al. N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow? Clin Pharmacol Ther 1997; 62: 261-71
12. Bendriss EK, Bechtel YC, Paintaud G, et al. Acetylation polymorphism expression in patients before and after liver transplantation: influence of host / graft genotypes. Pharmacogenetics 1998; 8: 201-9
13. Pons G, Rey E, Carrier O, et al. Maturation of AFMU excretion in infants. Fundam Clin Pharmacol 1989; 3: 589-95
14. Pariente-Khayat A, Rey E, Gendrel D, et al. Isoniazid acetylation metabolic ratio during maturation in children. Clin Pharmacol Ther 1997; 62: 377-83
15. Bechtel PR, Bechtel Y. N-acetyltransferase. In: Alván G, Balant LP, Bechtel PR, Boobis AR, Gram LF, Pithan K, eds. European consensus conference on pharmacogenetics. Brussels: Commission of the European Communities, 1990: 161-9
16. Caporaso N, Landi MT, Vineis P. Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiological evidence. Pharmacogenetics 1991; 1: 4-19
17. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983; 33: 591-602
18. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984; 17: 459-64
19. Fuhr U, Rost KL, Engelherdt R, et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996; 6: 159-76
20. Bechtel YC, Bonaiti-Pellie C, Poisson N, et al. A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther 1993; 54: 134-41
21. Rostami-Hodjegan A, Nurminen S, Jackson PR, et al. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6: 121-49
22. Ellard GA, Gammon PT. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens. Br J Clin Pharmacol 1977; 4: 5-14
23. Lennard MS. Genetically determined adverse drug reactions. Drug Safety 1993; 9: 60-77
24. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37: 25-79
25. Pralong E, Gascon MP, Dayer P. Conséquences cliniques du polymorphisme génétique de la N-acétylation. Med Hyg 1986; 44: 1162-70
26. Woosley RL, Drayer DE, Reidenberg MM, et al. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med 1978; 298: 1157-9
27. Spielberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996; 24: 509-19
28. Wolkenstein P, Carrière V, Charue D, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995: 5: 255-8
29. Zielinska E. Niewiarowski W, Bodalski J. The arylamine N-acetyltransferase (NAT2) polymorphism and the risk of adverse reactions to co-trimoxazole in children. Eur J Clin Pharmacol 1998; 54: 779-85
30. Rains CP. Noble S, Faulds D. Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995; 50: 137-56
31. Sabbagh N, Delaporte E, Marez D, et al. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 1997; 7: 131-5
32. Bluhm RE, Adedoyin A. McCarver DG, et al. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther 1999; 65: 598-605
33. Ratain MJ, Rosner G, Allen SL, et al. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol 1995; 13: 741-7
34. Hein DW, Doll MA, Rustan TD, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14: 1633-8
35. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988; 948: 37-66
36. Rodriguez JW, Kirlin WG, Ferguson RJ, et al. Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch Toxicol 1993; 67: 445-52
37. Stanley LA, Coroneos E, Cuff R, et al. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J Histochem Cytochem 1996; 44: 1059-67
38. Rothman N, Bhatnagar VK, Hayes RB, et al. The impact of interindividual variation in NAT2 activity on benzidine urinary metabolites and urothelial DNA adducts in exposed workers. Proc Natl Acad Sci U S A 1996; 93: 5084-9
39. Brockmöller J, Cascorbi I, Kerb R, et al. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996; 56: 3915-25
40. Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 2000; 10: 115-22
41. Green J, Banks E, Berrington A, et al. N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. Br J Cancer 2000; 83: 412-7
42. Lang NP, Chu DZJ, Hunter CF, et al. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg 1986; 121: 1259-61
43. Ladero JM, Gonzalez JF, Benitez J, et al. Acetylator polymorphism in human colorectal carcinoma. Cancer Res 1991; 51: 2098-100
44. Hubbard AL, Harrison DJ, Moyes C, et al. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions. Gut 1997; 41: 229-34
45. Roberts-Thomson IC, Ryan P, Khoo KK, et al. Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet 1996; 347: 1372-4
46. Gil JP. Lechner MC. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis 1998; 19: 37-41
47. Ilett KF, Ingram DM, Carpenter DS, et al. Expression of monomorphic and polymorphic N-acetyltransferases in human colon. Biochem Pharmacol 1994; 47: 914-7
48. Hubbard AL, Moyes C, Wyllie AH, et al. N-acetyl transferase 1: two polymorphisms in coding sequence identified in colorectal cancer patients. Br J Cancer 1998; 77: 913-6
49. Brockton N, Little J, Sharp L, et al. N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000; 151: 846-61
50. Agundez JAG, Olivera M, Ladero JM, et al. Inscreased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 1996; 6: 501-12
51. Agundez JA, Ladero JM, Olivera M, et al. Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients. Oncology 1995; 52: 7-11
52. Ambrosone CB, Freudenheim JL, Graham S, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 1996; 276: 1494-501
53. Delfino RJ, Smith C, West JG, et al. Breast cancer, passive and active cigarette smoking and N-acetyltransferase 2 genotype. Pharmacogenetics 2000; 10: 461-9
54. Cascorbi I, Brockmoller J, Mrozikiewicz PM, et al. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 1996; 56: 3961-6
55. Saarikoski ST, Reinikainen M, Anttila S, et al. Role of NAT2 deficiency in susceptibility to lung cancer among abestos-exposed individuals. Pharmacogenetics 2000; 10: 183-5
56. Hirvonen A, Saarikoski ST, Linnainmaa K, et al. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. J Natl Cancer Inst 1996; 88: 1853-6
57. Pluth JM, Nelson DO, Ramsey MJ, et al. The relationship between genotype and chromosome aberration frequencies in a normal adult population. Pharmacogenetics 2000; 10: 311-9
58. Mrozikiewicz PM, Drakoulis N, Roots I. Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin Pharmacol Ther 1994; 56: 626-34
59. Agundez JA, Menaya JG, Tejeda R, et al. Genetic analysis of the NAT2 and CYP2D6 polymorphisms in white patients with non-insulin-dependent diabetes mellitus. Pharmacogenetics 1996; 6: 465-72
60. Korpinen E, Groop PH, Rautio A, et al. N-acetyltransferase-2 polymorphism, smoking and type 1 diabetic nephropathy. Pharmacogenetics 1999; 9: 627-33
61. Zielinska E, Niewiarowski W, Bodalski J, et al. Arylamine N-acetyltransferase (NAT2) gene mutations in children with allergic diseases. Clin Pharmacol Ther 1997; 62: 635-42
62. Gawronska-Szklarz B, Luszawska-Kutrzeba T, Czaja-Bulsa G, et al. Relationship between acetylation polymorphism and risk of atopic diseases. Clin Pharmacol Ther 1999; 65: 562-9
63. Gawronska-Szklarz B, Pawlik A, Czaja-Bulsa G, et al. Genotype of N-acetyltransferase-2 (NAT2) polymorphism in children with imminoglobulin E-mediated food allergy. Clin Pharmacol Ther 2001; 69: 372-8
64. Bandmann O, Vaughan J, Holmans P, et al. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 1997; 350: 1136-9
65. Agundez JA, Rodriguez I, Olivera M, et al. CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians. Age Ageing 1997: 26: 147-51